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(236/296). The total duration of treatment was restricted
to 48 hours for 360 of 366 (98%) patients. Global con-
formity, defined as the combination of the five major cri-
teria, accounted for 52% (201/386) of patients undergo-
ing THR surgery. After multivariate analysis, a statistically
significant association was found between the global con-
formity and the prescribers (p  0.03). The interventions
during 1999 (AOR 0.61; 95% CI 0.40–0.92) were associ-
ated with a risk of non-conformity. Adherence to guide-
lines for antibiotic prophylaxis practice was not associated
with prescriber’s characteristics.
CONCLUSIONS: Although French guidelines were re-
cently published, the appropriateness of antibiotic pro-
phylaxis in THR surgery could still be enhanced espe-
cially in terms of the rational choice of a molecule and
timing of the first injection.
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OBJECTIVE: To facilitate evaluation and comparison of
cost-effectiveness results for varicella and pneumococcal
conjugate vaccination with respiratory syncytial virus
(RSV) prophylaxis using palivizumab by standardizing
cost and benefit results from published studies.
METHODS: MEDLINE search identified English lan-
guage cost-effectiveness studies for the three interven-
tions. Prophylaxis recommendations by the American
Academy of Pediatrics were examined. Results were dis-
counted by 5% and costs were inflated to 1997 dollars
using the Medical Care component of the CPI.
RESULTS: From the societal perspective, the cost per life
year saved was $144,000 for pneumococcal vaccine and
$54,000 for palivizumab RSV prophylaxis, but varicella
vaccine saved money. From the payers’ perspective, the
cost per life year saved was $278,000 for pneumococcal
vaccine, $55,000 for RSV prophylaxis and $23,000 for va-
ricella vaccine. Payers’ cost to avoid hospitalization for
RSV infection was $13,000. An avoided varicella case cost
$6 and it cost $2400 to avoid a major varicella sequela,
and each case of pneumococcus avoided cost $103,000.
CONCLUSION: Prevention of avoidable childhood mor-
bidity and mortality may cause incremental costs to payers
but would be a rational policy from a societal point of view.
Costs associated with RSV prophylaxis of high-risk infants
with palivizumab do not appear unreasonable compared
with the cost-effectiveness of two recent vaccines recom-
mended for universal use in healthy children in the US.
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OBJECTIVE: The Recurrent Genital Herpes Quality of
Life questionnaire (RGHQoL) is a needs-based quality of
life (QoL) instrument specifically for use with recurrent
genital herpes (RGH). It has been shown to have excel-
lent psychometric properties. However, it cannot cur-
rently be used in the calculation of utility for economic
analyses. Existing utility instruments cover symptoms
and functioning, rather than QoL. Concern has been ex-
pressed over their relevance for RGH and, consequently,
their ability to show differences between interventions.
The aim of this project is to explore the potential for us-
ing the RGHQoL to produce meaningful utility scores.
The first stage was to investigate whether a preference
elicitation exercise was required or whether RGHQoL re-
sponses could be incorporated directly into utility analy-
ses. This paper presents findings from the first stage.
METHODS: Structured interviews were conducted with
100 RGH patients. Patients undertook preference exer-
cises (paired comparison and ranking) with six RGHQoL
items and completed the RGHQoL. Thurstone’s law of
comparative judgement was used to calculate item prefer-
ence weights. These were compared with item severity
weights derived via application of the Rasch model to
RGHQoL responses.
RESULTS: Item ordering of severity was: B-E-D-C-A-F
(paired comparisons), B-C-D-E-A-F (ranking) and F-A-D-
C-E-B (Rasch severity). The paired comparisons and
ranking exercises resulted in different ordering of some
items, even though the methods are considered direct al-
ternatives for eliciting preference information. The Rasch
severity and preference weights provided very different
orderings. For example, the most severe item according
to patients’ responses to the RGHQoL was judged the
least severe in the paired comparison and ranking situa-
tions.
CONCLUSIONS: The results suggest that individuals’
ratings of what would have the most impact on them are
very different from what actually has an impact. RGHQoL
responses cannot be used directly in place of preference
elicitation.
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OBJECTIVES: This paper reports on the development of
and psychometric validation of the Influenza Daily Dis-
ruption Questionnaire (IDDQ), a short new instrument
